Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.

Foltynie T. et al, (2023), Brain, 146, 2717 - 2722

NPC1 variants are not associated with Parkinson's disease, REM-sleep behavior disorder or dementia with Lewy bodies in European cohorts.

Somerville EN. et al, (2023), Neurobiol Aging, 127, 94 - 98

Reward insensitivity is associated with dopaminergic deficit in rapid eye movement sleep behaviour disorder

Barber TR. et al, (2023), Brain, 146, 2502 - 2511

B lymphocyte responses in Parkinson's disease and their possible significance in disease progression.

Scott KM. et al, (2023), Brain Commun, 5

Co-Existent Probable RBD and PD: Disease Progression, Medication Response, and Clinical Trial Implications

Zou H. et al, (2023), Movement Disorders Clinical Practice

Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.

Gonzalez-Robles C. et al, (2023), J Parkinsons Dis, 13, 1013 - 1035

Neurofilament light levels predict clinical progression and death in multiple system atrophy.

Chelban V. et al, (2022), Brain, 145, 4398 - 4408

Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects.

Krohn L. et al, (2022), Nat Commun, 13

Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes

Pavelka L. et al, (2022), npj Parkinson's Disease, 8

Universal clinical Parkinson's disease axes identify a major influence of neuroinflammation.

Sandor C. et al, (2022), Genome Med, 14

Association between the LRP1B and APOE loci in the development of Parkinson's disease dementia.

Real R. et al, (2022), Brain

Identification of a possible proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSF

WINCHESTER L. and NEVADO-HOLGADO A., (2022), Brain Communications

Publisher Correction: Age at onset as stratifier in idiopathic Parkinson's disease - effect of ageing and polygenic risk score on clinical phenotypes.

Pavelka L. et al, (2022), NPJ Parkinsons Dis, 8

Exploration of whether socioeconomic factors affect the results of priority setting partnerships: updating the top 10 research priorities for the management of Parkinson's in an international setting.

Bowring F. et al, (2022), BMJ Open, 12

Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking Parkinson's cohorts.

Lawton M. et al, (2022), J Neurol Neurosurg Psychiatry

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies

Poggiolini I. et al, (2022), Brain, 145, 584 - 595

Dietary Patterns and Nonmotor Symptoms in Parkinson's Disease: A Cross-Sectional Analysis.

Lawrie S. et al, (2022), J Am Nutr Assoc, 1 - 10

A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's disease.

Lo C. et al, (2022), J Neurol Neurosurg Psychiatry

Author Correction: Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations.

Vignando M. et al, (2022), Nat Commun, 13

Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations.

Vignando M. et al, (2022), Nat Commun, 13

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?